Month

May 2024
On 28th May 2024 it was held the STAND4Kids 3rd Progress Meeting, at the Portuguese Society of Pediatrics (SPP) facilities, dedicated to the topic “Networks supporting pediatric trials in Europe“. This meeting was held with a hybrid format with online streaming at the Youtube channel of the Lisbon School of Medicine. This meeting was a...
Continue Reading
Under the International Clinical Trails week, we reinforce our mission and commitment in establishing a sustainable, lean, fit-for-purpose, national pediatric trial network that facilitates high-quality, child/family- and clinically-relevant, operationally efficient pediatric clinical trials in Portugal. The STAND4Kids National Hub for pediatric clinical trials of the conect4children consortium has a national network of 10 research sites...
Continue Reading
Our team attended the 3rd National Meeting on Clinical Research and Biomedical Innovation, an initiative promoted by the Agency for Clinical Research and Biomedical Innovation – AICIB – on May 21 in Lisbon. This meeting is a forum for sharing, reflecting and discussing the most current issues in Clinical Research and Biomedical Innovation in Portugal,...
Continue Reading
On May 17, Ricardo Fernandes, Project Lead of our STAND4Kids network, participated in the Workshop on “Collaboration between researchers, patients, health professionals, sponsor, academia and the community to strengthen clinical trials”. This Workshop was developed under the Conference “Clinical Trials | Research that gives hope to patients and brings a better life to all”. The...
Continue Reading
The STAND4Kids Project Lead, Ricardo Fernandes presented the topic “Conect4children Stichting(c4c-S) – pan-European paediatric clinical trial network” at the 5th Nordic Conference on Paediatric Medicines, which was held on 14th and 15th May, in Helsinki, Finland. This edition was dedicated to the future of Pediatric and Orphan clinical trials. This conference was organized in a...
Continue Reading
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389. The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA